Free Trial
NASDAQ:PLSE

Pulse Biosciences Q3 2025 Earnings Report

Pulse Biosciences logo
$18.99 +0.87 (+4.80%)
Closing price 04:00 PM Eastern
Extended Trading
$19.05 +0.06 (+0.29%)
As of 05:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulse Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.31
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulse Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.50 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulse Biosciences Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, October 29, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Pulse Biosciences Earnings Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Pulse Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulse Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulse Biosciences and other key companies, straight to your email.

About Pulse Biosciences

Pulse Biosciences (NASDAQ:PLSE). is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions. The CellFX System has received FDA 510(k) clearance and CE Mark approval in Europe, enabling commercial sales in the United States and select international markets. Beyond dermatology, Pulse Biosciences is exploring the NPS platform’s potential in oncology, immuno-oncology, wound healing and bacterial decontamination—areas that could benefit from nonthermal cellular disruption.

Founded in 2013 and headquartered in Hayward, California, Pulse Biosciences operates in North America and Europe, working closely with key opinion leaders in dermatology and medical research institutions. The company is led by President and Chief Executive Officer Vivek Chopra, who brings extensive experience in medical device development and commercialization. As Pulse Biosciences advances its clinical programs and expands its commercial footprint, it aims to establish TNP technology as a versatile tool across multiple therapeutic areas.

View Pulse Biosciences Profile

More Earnings Resources from MarketBeat